What the FDA decided on Gefurulimab for Generalized myasthenia gravis
The FDA approved Gefurulimab for generalized myasthenia gravis (anti-AChR antibody-positive adults).
The FDA has approved Klygefa (gefurulimab) for adults with generalized myasthenia gravis who test positive for antibodies against the acetylcholine receptor (AChR). Drugs@FDA lists the approval on November 13, 2026, and AstraZeneca announced it on November 16. Klygefa blocks complement protein C5 and is injected under the skin once a week, after a first loading dose based on body weight.
In the Phase 3 PREVAIL trial of 260 adults, MG-ADL daily-living scores fell 4.2 points on Klygefa and 2.6 on placebo at week 26. Klygefa carries a boxed warning for serious meningococcal infections, like the other C5 blockers for myasthenia gravis, and is available only through a restricted program called the KLYGEFA REMS.
Meningococcal vaccines are needed at least 2 weeks before the first dose. Injection site reactions were the most common side effect in the trial.
Who the Gefurulimab decision matters to
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies attack acetylcholine receptors at the neuromuscular junction, preventing proper muscle contraction.
The condition is manageable with medications and other treatments that suppress the immune response.
Prevalence: 1 in 5,000 people. See our full Myasthenia Gravis page for current treatments, recruiting trials, and community resources.
How Gefurulimab works
Gefurulimab: bispecific nanobody with 2 parts that blocks complement protein C5 and also binds the blood protein albumin, which lets it last long enough for weekly dosing. Our full Gefurulimab profile covers how it works, side effects in plain language, and its trial history.
Where Myasthenia Gravis treatment stands today
Read our full Myasthenia Gravis treatment summary
Myasthenia gravis treatment options are expanding rapidly with new targeted therapies entering clinical trials. FcRn inhibitors reduce pathogenic antibody levels, while complement inhibitors block the destruction of acetylcholine receptors.
Another FcRn blocker, nipocalimab (Imaavy), was FDA approved in April 2025 for generalized MG in adults and children 12 and older who are AChR or MuSK antibody positive, and is given by IV infusion every 2 weeks after a first loading dose. Trials are designed for specific antibody subtypes, with the most options available for AChR-positive patients.
MuSK-positive patients are increasingly included in FcRn inhibitor and complement studies, while seronegative MG patients have the fewest dedicated trial options. Pyridostigmine (Mestinon) is almost always allowed during trials.
If you are on a targeted therapy like Vyvgart or Soliris and want to join a new trial, expect a washout period of 4 weeks to 4 months depending on the drug class.
Your MG-ADL score, MGFA classification, and recent flare history all factor into trial eligibility. The Myasthenia Gravis Foundation of America tracks trial opportunities.
Your neuromuscular specialist can help determine which emerging therapies match your antibody subtype, disease severity, and current medication regimen.
The Myasthenia Gravis page has every treatment and trial →Meanwhile, 118 Myasthenia Gravis studies are recruiting or not yet recruiting
The FDA's decision does not end research on Myasthenia Gravis. The most recently updated:
Earlier-stage drugs Trial Friend tracks for Myasthenia Gravis
You'll hear about future FDA decisions and new recruiting trials for Myasthenia Gravis. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.
We never share your email. Stop anytime from the link in every email. Privacy policy
Frequently asked questions
Has the FDA decided on Gefurulimab?
The FDA has already decided. It approved the application.
Details: the outcome and what it means are at the top of this page.
What was Gefurulimab approved for?
The FDA approved AstraZeneca (Alexion)'s BLA for Gefurulimab in Generalized myasthenia gravis (anti-AChR antibody-positive adults).
What to know: The FDA has approved Klygefa (gefurulimab) for adults with generalized myasthenia gravis who test positive for antibodies against the acetylcholine receptor (AChR). Drugs@FDA lists the approval on November 13, 2026, and AstraZeneca announced it on November 16. Klygefa blocks complement protein C5 and is injected under the skin once a week, after a first loading dose based on body weight. In the Phase 3 PREVAIL trial of 260 adults, MG-ADL daily-living scores fell 4.2 points on Klygefa and 2.6 on placebo at week 26. Klygefa carries a boxed warning for serious meningococcal infections, like the other C5 blockers for myasthenia gravis, and is available only through a restricted program called the KLYGEFA REMS. Meningococcal vaccines are needed at least 2 weeks before the first dose. Injection site reactions were the most common side effect in the trial.
How it works: Bispecific nanobody with 2 parts that blocks complement protein C5 and also binds the blood protein albumin, which lets it last long enough for weekly dosing.
More: the Gefurulimab drug page explains it in plain language.
Is there already an FDA-approved treatment for Myasthenia Gravis?
Yes. Trial Friend's drug list includes 8 FDA-approved drugs for Myasthenia Gravis.
Approved: Soliris (eculizumab), Vyvgart (efgartigimod alfa), Ultomiris (ravulizumab), Rystiggo (rozanolixizumab), Zilbrysq (zilucoplan), Uplizna (inebilizumab), Imaavy (nipocalimab), Klygefa (gefurulimab).
Also coming: Cemdisiran, Imeroprubart, mivocabtagene autoleucel.
Check: the Myasthenia Gravis page also searches FDA drug labels for approved treatments.
What did the Gefurulimab trials show?
PREVAIL (NCT05556096) is a Phase 3, double-blind, placebo-controlled trial run at 113 sites in 20 countries. It randomized 260 adults with AChR antibody-positive generalized myasthenia gravis and an MG-ADL score of 5 or more to gefurulimab (131) or placebo (129) for 26 weeks, on top of their usual treatment, and 249 finished that period.
More: the Gefurulimab drug page has the full trial history and sources.
What are the side effects of Gefurulimab?
Boxed warning: Klygefa increases the risk of serious and life-threatening infections caused by Neisseria meningitidis, the bacteria behind meningococcal disease. Meningococcal vaccines must be completed or updated at least 2 weeks before the first dose unless delaying treatment is riskier, and people stay at higher risk even after vaccination, so early signs of infection need urgent attention.
More: the Gefurulimab drug page has the label's warnings in full.
How much will Gefurulimab cost?
Trial Friend does not list a price for Gefurulimab. What you pay depends on your insurance and on help from the drugmaker or a charity fund.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Gefurulimab decision?
The FDA approved Gefurulimab for Generalized myasthenia gravis (anti-AChR antibody-positive adults) on November 13, 2026.
Next steps: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
Where this outcome comes from
The outcome on this page comes from Drugs@FDA, BLA 761488, Nov 13 2026. This page rechecks against our calendar, which is re-verified daily.